ALS therapy EKZ-102 on track to enter clinical testing in 2026
EKZ-102, Eikonizo Therapeutics‘s experimental oral therapy for amyotrophic lateral sclerosis (ALS), is on track to enter early clinical testing in 2026, according to an announcement from the company. EKZ-102 is designed to block the activity of a protein called HDAC6. A team led by scientists at Eikonizo…